IP Library › Granted Patent US 10,086,041
Granted Patent B2
US 10,086,041 · App. 15/387,201 · Granted Oct 2, 2018

Syndecan-4 proteoliposomes for enhanced cutaneous wound healing and minimized inflammatory immune response

Inventors: Aaron B. Baker (Austin, TX); Subhamoy Das (Austin, TX)
Assignee: Board of Regents, The University of Texas System
A61K38/177A61K9/127A61K38/179A61K38/1858A61K9/0014A61K9/1277
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,086,041
App. No.
15/387,201
Granted
Oct 2, 2018
Kind
B2
Abstract

Disclosed herein are compositions and articles for wound healing that contain proteovesicles, comprising a syndecan polypeptide embedded in a lipid vesicle, and a PDGF polypeptide. Also disclosed is the use of these compositions to enhance wound healing.

Claims (15)

1. A composition comprising: a) a proteovesicle comprising a syndecan-4 polypeptide embedded in a lipid vesicle, and b) a growth factor polypeptide, wherein the growth factor polypeptide is platelet derived growth factor BB (PDGF-BB).

2. The composition of claim 1 , wherein the composition further comprises a PDGF receptor embedded in the lipid vesicle.

3. The composition of claim 2 , wherein the PDGF receptor binds to PDGF-BB.

4. The composition of claim 2 , wherein the PDGF receptor is PDGFRα, PDGFRβ, or combinations, or heterodimers thereof.

5. The composition of claim 1 , wherein the PDGF-BB polypeptide and the proteovesicle are encapsulated in a biodegradable microbead.

6. The composition of claim 5 , wherein the microbead comprises a biocompatible hydrogel.

7. The composition of claim 6 , wherein the biocompatible hydrogel comprises a polysaccharide.

8. The composition of claim 7 , wherein the biocompatible hydrogel comprises alginate.

9. The composition of claim 5 , wherein the microbead is from 1 μm in diameter up to 3 μm in diameter.

10. The composition of claim 1 , wherein the composition further comprises a wound dressing.

11. The composition of claim 1 , wherein the PDGF-BB polypeptide and the proteovesicle are encapsulated in a biodegradable microcapsule.

12. A method for enhancing wound healing in a subject, comprising administering to a subject in need thereof therapeutically effective amounts of (a) a proteovesicle comprising a syndecan-4 polypeptide embedded in a lipid vesicle and (b) a growth factor polypeptide, wherein the growth factor polypeptide is PDGF-BB.

13. The method of claim 12 , wherein the proteovesicle and the PDGF-BB polypeptide are co-administered to the subject.

14. The method of claim 12 , wherein the wound is a chronic wound.

15. The method of claim 12 , wherein the wound is a skin wound.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 21, 2017
From: BAKER, AARON B.; DAS, SUBHAMOY
To: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Reel/Frame 041658/0107 →
CONFIRMATORY LICENSE Recorded Feb 17, 2017
From: UNIVERSITY OF TEXAS, AUSTIN
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 041747/0152 →
Continuity (2)
Provisional Application 62274501 · Jan 4, 2016
Related Publication 20170189479A1 · Jul 6, 2017